Investigational Bispecific Antibody Etentamig Shows Significant Promise in Advanced Multiple Myeloma Trial
"Etentamig demonstrates a remarkable 74% response rate in heavily pretreated multiple myeloma patients, significantly outperforming standard care and offering a potential paradigm shift in accessibility for advanced disease." AbbVie has…